FEND for TB supplement to accelerate BLINK X development

Rbhs-New Jersey Medical School, Newark NJ

Investigators

Linked publications, trials & patents

Abstract

ABSTRACT The goal of this supplement is to perform assay development, optimization and analytic assessments of the BLINK ONE, a novel tuberculosis identification and drug resistance testing system, potentially suitable for point of care assessment of all known anti-tuberculosis drugs. This project will help develop a new way to easily test for many genetic mutations in a single test using a simple device that could be used at the point of care. When applied to tuberculosis, most types of drug resistance could be easily and rapidly diagnosed. This could vastly simplify treatment decisions and potentially save hundreds of thousands of lives.